All
Cobrabio and ViroMed Join Together for R&D Biomanufacturing
August 12th 2008Cobra Biomanufacturing Plc (Keele, UK), a manufacturer of biopharmaceuticals, has extended its manufacturing agreement and intends to form a joint venture with ViroMed Co. Ltd. (Seoul, Korea), a specialist in the development of DNA and protein-based therapeutics.
Denny Kraichely Joins Editorial Advisory Board of BioPharm International
August 12th 2008Denny Kraichely, PhD, principal research scientist and group leader of pharmaceutical development and marketed product support at Centocor R&D, Inc. (Radnor, PA), a Johnson & Johnson Company, has joined the Editorial Advisory Board of BioPharm International.
GeoVax Partners with Vivalis for Using EBx Technology to Manufacture MVA HIV/AIDS Vaccine
August 12th 2008GeoVax Labs, Inc. (Atlanta, GA) and Vivalis (Nantes, France) have signed a letter of intent (LOI) for joint collaboration and commercial license using Vivalis’s EBx technology to manufacture the MVA component of GeoVax’s HIV-1 vaccine.
Florida Biologix Signs cGMP Agreement with National Taiwan University Hopsital
August 12th 2008Florida Biologix (Alachua, FL), a biopharmaceutical development and contract manufacturing organization, has entered into a current good manufacturing practices (cGMP) manufacturing agreement with the National Taiwan University Hospital (Taipei, Taiwan).
Determining Critical Quality Attributes Forms the Foundation for QbD Implementation
August 12th 2008Since the principles of Quality by Design (QbD) for pharmaceutical manufacturing first emerged a few years ago, many companies have been struggling to understand the key concept of design space?what it is exactly, and how to establish it.
Broken Vials of Herceptin May Lead to Loss in Sterility
July 11th 2008Genentech (South San Francisco, CA) has informed healthcare professionals that an increased number of complaints have been received regarding damaged and broken vials of Herceptin 440 mg and BWFI (bacteriostatic water for injection) diluent.
Roche Introduces Program to Facilitate Corporate Pandemic Stockpiling of Tamiflu
July 9th 2008Roche (Nutley, NJ) has introduced a flexible purchase program that will allow US businesses to maintain access to their own stockpile of Tamiflu for use in a pandemic situation, with limited upfront investment and more adaptability to deal with unknown factors inherent in pandemic planning.